Management of precocious puberty

Management of precocious puberty

The objectives of treatment for children with central precocious puberty (CPP) are to avoid psychosocial problems caused by early pubertal development and to normalize adult height (AH). A long-acting GnRH analog is the treatment of choice for CPP. GnRH analog administration effectively arrests further development of secondary sex characteristics, slows bone age (BA) maturation, increases puber...

Evaluation and management of precocious puberty.

Genetic and environmental factors are implicated in the timing of puberty (1). Human studies have shown a relationship between body mass index or body fat, dietary and physical activity with the timing of puberty (2, 3, 4). More recently a G-protein coupled receptor, GPR54 and its ligand Kisspeptin have been identified as important signals in pubertal induction (5). The role of leptin in the pu...

Precocious Puberty

From the Department of Pediatric Endocrinology and Diabetology, INSERM Unité 690, and Centre de Référence des Maladies Endocriniennes de la Croissance, Robert Debré Hospital and University of Paris 7 — Denis Diderot, Paris (J.-C.C., J.L.). Address reprint requests to Dr. Carel at Endocrinologie Diabétologie Pédiatrique and INSERM U690, Hôpital Robert Debré, 48, Blvd. Sérurier, 75935 Paris CEDEX...

Precocious Puberty.

Precocious puberty (PP) has traditionally been defined as pubertal changes occurring before age 8 years in girls and 9 years in boys. A secular trend toward earlier puberty has now been confirmed by recent studies in both the United States and Europe. Factors associated with earlier puberty include obesity, endocrine-disrupting chemicals (EDC), and intrauterine growth restriction. In 1997, a st...

Precocious Puberty